Control Resonant Tracks Well Ahead of Launch, Even as Remedy's Q2 Numbers Dip
- Sagar Mankar
- 4 hours ago
- 3 min read
Remedy Entertainment posted a revenue decline in both the second quarter and first half of 2026, as the studio pushed more marketing spend behind Control Resonant ahead of its launch.
CEO Jean-Charles Gaudechon said the numbers were expected, and he remains confident about how Resonant is shaping up before its September 24 release.
Key numbers
Remedy's Q2 2026 figures:
Revenue: €10.2 million, down 40 percent year over year
EBITDA: negative €2.4 million
Operating loss (EBIT): €3.9 million, compared to a €0.5 million loss in the same quarter last year
Cash flow from operations: negative €0.7 million
H1 2026 figures:
Revenue: €23.3 million, down 23.1 percent
EBITDA: €0.5 million
Operating loss (EBIT): €2.9 million, compared to a €0.8 million profit in the prior year period
Cash flow from operations: €7.6 million
Why did revenue drop?
Remedy pointed to two main factors behind the decline.
FBC: Firebreak launched during the comparison period last year, giving that quarter a revenue boost that this year's quarter did not have.
On top of that, Remedy ramped up marketing spend for Control Resonant, which ate into profitability even though it was a planned move.
Revenue from game sales and royalties came in at €3.8 million, down from €9.5 million a year earlier. Development fees tied to Resonant and the Max Payne 1 & 2 remake totaled €6.4 million, slightly down from €7.4 million in the previous period.
What's happening with Control Resonant?
Pre-orders for Resonant are already showing strong early demand. The game ranked among the top3 pre-ordered PlayStation titles in the United States, Germany, and Brazil during its campaign window, and it has crossed 1.5 million wishlists across platforms as of August 11.
"Our data indicates the game is tracking well against comparable titles in its launch window," Gaudechon said. "In a competitive autumn window, we believe the distinctiveness and quality of the game will make it stand out. Combined with the release window becoming slightly less crowded since our original reveal, we remain confident in our positioning."
He also credited the wider studio for keeping things on track while Resonant absorbs most of the attention:
"Along the road to our largest and most ambitious release to date, our existing catalogue has provided a solid backbone, and our other development projects advanced in line with plans, with our new project moving to production readiness."
Looking ahead to launch, Gaudechon added:
"Early signals and commercial metrics give us confidence in the game's potential, but our focus remains on bringing an outstanding game to the market and letting the results speak. I personally see the game getting stronger week by week, and our marketing accelerates further in the third quarter."
How did the existing catalogue perform?
No new titles launched during the quarter, but Remedy's back catalogue kept contributing:
Control (2019) saw a sales increase in Q2, helped by ongoing marketing tied to Resonant
Alan Wake 2 passed 3 million lifetime sales during the quarter
Alan Wake 2 and Alan Wake Remastered royalties came entirely from consumer sales, with no platform deal accruals this time around
The rest of the Alan Wake franchise sold at a normal back-catalogue pace
What's next for Remedy?
Remedy's development pipeline currently includes three projects:
Control Resonant, published by Remedy Entertainment, in full production and set to launch worldwide on September 24, 2026
A new, currently unnamed project from Remedy Entertainment, which has reached "production readiness"
The Max Payne 1 & 2 remake, published by Rockstar Games, also in full production
Remedy kept its full-year 2026 outlook unchanged, still expecting both revenue and EBITDA to grow compared to last year. The studio's longer-term targets remain in place too, aiming to double 2024 revenue by 2027 and hit a 30% EBITDA margin by the same year.
Comments